Dynamic42 raises mid-seven-figure investment in Series A financing round
Flexible and customized Organ-on-Chip Solutions for Advanced Drug Testing
Innovative organ-on-chip specialist Dynamic42 GmbH has closed a mid-seven-figure financing round. The company, which was spun off from the “Center of Sepsis Control and Care” of the University Hospital Jena in March 2018, was able to convince both the previous lead investor bm-t beteiligungsmanagement thüringen gmbh (bm-t) and a family office from the health sector to invest and support the growth, development and vision of the company in the coming years as part of a growth financing round (Series A).
Decisive for the investment was above all the added value that Dynamic42 generates with its technology and its use for society, such as the increase of drug safety, the reduction of drug development costs and the reduction of animal testing. Here, Dynamic42´s technology offers a very good alternative to current systems used in the development of active compounds and has a high market potential. “We can proudly announce that we have created an up-and-coming company and are extremely pleased about this strategically important investment. In times of a more challenging investment market, it is a strong signal for us that our technology and vision possess high potential,” said Managing Directors Dr. Martin Raasch and Dr. Knut Rennert.
Flexible and customized Organ-on-Chip Solutions for Advanced Drug Testing
The special feature of the new chip is the spatial design with three culture chambers. This enables the cultivation of complex, three-dimensional tissue cultures. Until now, many organ-on-chip applications have used chips with two very narrow chambers on top of each other. However, this quickly leads to limitations in terms of spatial dimensions. The technical integration of spheroids (spherical tissue structures) in chip formats with a simultaneously flowing culture medium has been difficult to design up to now. Applications such as biologically complex tumour models in chip applications remained limited.
“The chip allows us to dive into completely new application areas for organ-on-chip technology, such as cancer research,” explains Dr. Martin Raasch, CEO of Dynamic42. “To improve the significance of research results that are transferable to the human organism, we have designed the chip architecture to be more complex. The main advantage for the user is that this does not complicate handling.”
Expanding the application areas of organ-on-chip technology
Dynamic42 offers its customers miniaturized human organ models (so-called organ-on-chip/ microphysiological systems) for drug testing. Dynamic42 is unique on the market due to its flexible and easily created customer-specific solutions based on its innovative technology platform. In addition, Dynamic42 is able to integrate essential components of the human immune system into its human organ models and to investigate their influence on drug compatibility. Customers can thus make initial judgements about the toxicity of drug candidates in humans even before animal testing in the preclinical phase of drug development and decide whether to continue or stop the development of an active substance.
“Dynamic42 GmbH has grown steadily since it was founded five years ago and has already been able to win well-known pharmaceutical companies as customers. We are convinced that Dynamic42, with its strong technology platform and motivated team, will play a leading role in the rapidly growing organ-on-chip market in the future,” said Stefan Jahn, Senior Investment Manager at bm-t.
With the investment, Dynamic42 will continue the further development of products and services, open new markets, recruit highly qualified personnel, further develop the company infrastructure as well as expand the property rights portfolio and sales infrastructure. An important milestone in the coming years will be the company´s internationalization, including entering the USA as the world’s largest pharmaceutical market.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Epistem Announces Partnership with The University of Manchester
Ventana announces collaboration to develop companion diagnostics for ImmunoGen's targeted anticancer agents
High-Tech Gründerfonds, Bayern Kapital and BioM AG to invest in Intana Bioscience GmbH
Heart hormone helps shape fat metabolism - Sanford-Burnham study shows that the pathway to losing fat is heavily influenced by a hormone produced in the heart
Low-carb diets linked to atherosclerosis and impaired blood vessel growth - Study suggests that popular diet regimen may have adverse effect on body's restorative capacity
Autoimmunity: immune cells escape therapy due to "exhausted" state - Researchers have succeeded in isolating and analyzing disease-causing T cells from the blood in autoimmune diseases
Fluidity Predicts Aggressiveness of Cancerous Tumours
Biogemma and Wageningen UR announce a collaboration in wheat drought tolerance research
Harvard Apparatus Acquires PanLab s.l. - A New Acquisition by Harvard Apparatus Expands its Behavioral Sciences Product Offerings
SCIO Automation Munich GmbH - Frankenthal, Germany
SRI Instruments Europe GmbH - Bad Honnef, Germany